Literature DB >> 18158057

Renal pelvic hemorrhage and acute renal failure associated with carboplatin therapy.

Srivilliputtur G Santhana Krishnan1, Brian VanderBrink, Gary Weiss, Pravin C Singhal, Hitesh H Shah.   

Abstract

A 44-year-old woman with ovarian cancer and normal renal function developed gross hematuria after carboplatin therapy. Laboratory investigation revealed elevated blood urea nitrogen and serum creatinine values. Computed tomography scan of the abdomen and pelvis with or without contrast revealed bilateral hydronephrosis with high-attenuation material within the left renal pelvis and both ureters consistent with blood. Delayed images at 3 hours revealed intense nephrogram with delayed excretion of contrast bilaterally. She underwent cystoscopy and placement of ureteral stent bilaterally. She had brisk diuresis with associated progressive decrease in serum creatinine to baseline value.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158057      PMCID: PMC2247434          DOI: 10.1016/j.urology.2007.08.059

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Authors:  Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

2.  Carboplatin and renal dysfunction.

Authors:  E Reed; J Jacob
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

3.  High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.

Authors:  M E Gore; A H Calvert; L E Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

4.  Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature.

Authors:  B R McDonald; S Kirmani; M Vasquez; R L Mehta
Journal:  Am J Med       Date:  1991-03       Impact factor: 4.965

5.  Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

Authors:  R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

6.  Carboplatin-related hematuria and acute renal failure.

Authors:  M Agraharkar; S Nerenstone; J Palmisano; A A Kaplan
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

Review 7.  Drugs five years later. Cisplatin.

Authors:  P J Loehrer; L H Einhorn
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

8.  A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Childrens Cancer Group.

Authors:  L J Ettinger; M D Krailo; P S Gaynon; G D Hammond
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

Review 9.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

10.  Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer.

Authors:  M Ozguroglu; O Sari; H Turna
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

  10 in total
  1 in total

1.  Design and synthesis of coumarin-based organoselenium as a new hit for myeloprotection and synergistic therapeutic efficacy in adjuvant therapy.

Authors:  Arup Ranjan Patra; Somnath Singha Roy; Abhishek Basu; Avishek Bhuniya; Arin Bhattacharjee; Subhadip Hajra; Ugir Hossain Sk; Rathindranath Baral; Sudin Bhattacharya
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.